Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness (PSYC) has confirmed July 7 for its pilot production run of the first legal amanita muscaria tincture product
  • The product will be for sale in the United States
  • ‘Calm’ will be the first legal Amanita Muscaria mushroom product to be sold in North America
  • Going forward the team is looking to produce a craft number of units that will be used to test all flavour profiles and share them with opinion leaders
  • Updates on the pilot run can be expected 24 to 48 hours after production
  • Psyched Wellness Ltd. (PSYC) is up over 15.30 per cent, trading at C$0.08 at 2:13 pm EST

Psyched Wellness Ltd. (PSYC) initial pilot production run for its first-to-market AME-1 product, ‘Calm’ is scheduled for July 7.

The product is presented as an extract which enables the mushroom’s ability to de-stress and facilitate restful sleep.

According to the company, the production of the product signals that the company is on track to transition from an R&D organization to a full-scale commercial consumer packaged goods (CPG) entity, generating revenue.

All Amanita Muscaria products produced by Psyched Wellness will be available over-the-counter and without a prescription.

Psyched hopes this will maximize distribution and listing potential. ‘Calm’ will be the first legal Amanita Muscaria mushroom product to be sold in North America.

COO of Psyched, Matthew Singh touched on the not so easy journey to get to this place. “Each calibration that improved our offering motivated the R&D, Operations, and Production teams to continue reformulating and optimizing until Calm reached its current form.”

“It was important for our team to stay focused and not rush what is arguably the most integral part of product development. Our entire company is excited to share this version of Calm with the world (starting with a release in the United States),” continued Singh.

In the future, the team is looking to produce a craft number of units that will be used to test all flavour profiles and share them with opinion leaders. Updates on the pilot run can be expected 24 to 48 hours after production.

Psyched Wellness Ltd. is a Canadian-based health supplements company with the objective to create premium mushroom-derived products. 

Psyched Wellness Ltd. (PSYC) is up over 15.30 per cent, trading at C$0.08 at 2:13 pm EST.

More From The Market Herald

" The Market Herald’s Weekly Cannabis Report. August 5, 2022.

1 | Top Story: High Tide Inc. (TSXV:HITI) acquires retail stores in B.C. and Alberta
Field Trip Health - CEO, Joseph del Moral.

" Field Trip (TSX:FTRP) receives conditional approval to list common shares of Field Trip Health & Wellness on the TSXV

The TSX Venture Exchange (TSXV) has issued conditional listing approval to Field Trip Health Limited (FTRP).

" Optimind Pharma (CSE:OMND) commences trading on the CSE

Optimind Pharma (OMND) will begin trading on the CSE under the ticker symbol OMND.